ISSN 1671-5411 CN 11-5329/R
Volume 18 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Please cite this article as: Merchant FM, Larson J, Darghosian L, Smith P, Kiani S, Westerman S, Shah AD, Hirsh DS, Lloyd MS, Leon AR, El-Chami MF. Prospective evaluation of health status, quality of life and clinical outcomes following implantable defibrillator generator exchange. J Geriatr Cardiol 2021; 18(9): 720−727. DOI: 10.11909/j.issn.1671-5411.2021.09.007
Citation: Please cite this article as: Merchant FM, Larson J, Darghosian L, Smith P, Kiani S, Westerman S, Shah AD, Hirsh DS, Lloyd MS, Leon AR, El-Chami MF. Prospective evaluation of health status, quality of life and clinical outcomes following implantable defibrillator generator exchange. J Geriatr Cardiol 2021; 18(9): 720−727. DOI: 10.11909/j.issn.1671-5411.2021.09.007

Prospective evaluation of health status, quality of life and clinical outcomes following implantable defibrillator generator exchange

doi: 10.11909/j.issn.1671-5411.2021.09.007
More Information
  •  BACKGROUND Little is known about health status and quality of life (QoL) after implantable cardioverter-defibrillator (ICD) generator exchange (GE). METHODS We prospectively followed patients undergoing first-time ICD GE. Serial assessments of health status were performed by administering the 36-Item Short Form Survey (SF-36). RESULTS Mean age was 67.5 ± 14.3 years, left ventricle ejection fraction (LVEF) was 36.5% ± 15.0% and over 40% of the cohort had improved LVEF to > 35% at the time of GE. SF-36 scores were significantly worse in physical/general health domains compared to domains of emotional/social well-being (P < 0.001 for each comparison). Physical health scores were significantly worse among those with medical comorbidities including diabetes, chronic obstructive pulmonary disease and atrial fibrillation. Mean follow-up was 1.6 ± 0.5 years after GE. Overall SF-36 scores remained stable across all domains during follow-up. Survival at 3 years post-GE was estimated at 80%. Five patients died during follow-up and most deaths were adjudicated as non-arrhythmic in origin. Four patients experienced appropriate ICD shocks after GE, three of whom had LVEF which remains impaired LVEF (i.e., < 35%) at the time of GE. CONCLUSION Patients undergoing ICD GE have significantly worse physical health compared to emotional/social well-being, which is associated with the presence of medical comorbidities. In terms of clinical outcomes, the incidence of appropriate shocks after GE among those with improvement in LVEF is very low, and most deaths post-procedure appear to be non-arrhythmic in origin. These data represent an attempt to more fully characterize the spectrum of QoL and clinical outcomes after GE.
  • loading
  • [1]
    Merchant FM, Quest T, Leon AR, El-Chami MF. Implantable cardioverter-defibrillators at end of battery life: opportunities for Risk (Re)-stratification in ICD recipients. J Am Coll Cardiol 2016; 67: 435−444.
    [2]
    Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877−883. doi: 10.1056/NEJMoa013474
    [3]
    Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225−237. doi: 10.1056/NEJMoa043399
    [4]
    Witt CM, Waks JW, Mehta RA, et al. Risk of Appropriate Therapy and Death Before Therapy After Implantable Cardioverter-Defibrillator Generator Replacement. Circ Arrhythm Electrophysiol 2018; 11: e006155.
    [5]
    Weng W, Sapp J, Doucette S, et al. Benefit of implantable cardioverter-defibrillator generator replacement in a primary prevention population-based cohort. JACC Clin Electrophysiol 2017; 3: 1180−1189. doi: 10.1016/j.jacep.2017.03.004
    [6]
    Merchant FM, Jones P, Wehrenberg S, et al. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. J Am Heart Assoc 2014; 3: e001289.
    [7]
    Madhavan M, Waks JW, Friedman PA, et al. Outcomes after implantable cardioverter-defibrillator generator replacement for primary prevention of sudden cardiac death. Circ Arrhythm Electrophysiol 2016; 9: e003283.
    [8]
    McCarthy KJ, Locke AH, Coletti M, et al. Outcomes following implantable cardioverter-defibrillator generator replacement in adults: a systematic review. Heart Rhythm 2020; 17: 1036−1042. doi: 10.1016/j.hrthm.2020.01.005
    [9]
    Merchant FM, Levy WC, Kramer DB. Time to shock the system: moving beyond the current paradigm for primary prevention implantable cardioverter-defibrillator use. J Am Heart Assoc 2020; 9: e015139.
    [10]
    Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367: 2275−2283. doi: 10.1056/NEJMoa1211107
    [11]
    Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 2013; 309: 1903−1911. doi: 10.1001/jama.2013.4598
    [12]
    Hayes V, Morris J, Wolfe C, Morgan M. The SF-36 health survey questionnaire: is it suitable for use with older adults? Age Ageing 1995; 24: 120−125. doi: 10.1093/ageing/24.2.120
    [13]
    Carroll DL, Hamilton GA. Long-term effects of implanted cardioverter-defibrillators on health status, quality of life, and psychological state. Am J Crit Care 2008; 17: 222−230; quiz 231. doi: 10.4037/ajcc2008.17.3.222
    [14]
    Carroll DL, Hamilton GA, Kenney BJ. Changes in health status, psychological distress, and quality of life in implantable cardioverter defibrillator recipients between 6 months and 1 year after implantation. Eur J Cardiovasc Nurs 2002; 1: 213−219. doi: 10.1016/S1474-5151(02)00040-3
    [15]
    Hamilton GA, Carroll DL. The effects of age on quality of life in implantable cardioverter defibrillator recipients. J Clin Nurs 2004; 13: 194−200.
    [16]
    Ooi SL, He HG, Dong Y, Wang W. Perceptions and experiences of patients living with implantable cardioverter defibrillators: a systematic review and meta-synthesis. Health Qual Life Outcomes 2016; 14: 160. doi: 10.1186/s12955-016-0561-0
    [17]
    Kinch Westerdahl A, Sjoblom J, Mattiasson AC, et al. Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life. Circulation 2014; 129: 422−429. doi: 10.1161/CIRCULATIONAHA.113.002648
    [18]
    Kramer DB, Kennedy KF, Noseworthy PA, et al. Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR. Circ Cardiovasc Qual Outcomes 2013; 6: 488−497. doi: 10.1161/CIRCOUTCOMES.111.000054
    [19]
    Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med 2017; 377: 41−51. doi: 10.1056/NEJMoa1609758
    [20]
    Krahn AD, Connolly SJ, Roberts RS, et al. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004; 147: 837−840. doi: 10.1016/j.ahj.2003.12.017
    [21]
    Krahn AD, Lee DS, Birnie D, et al. Predictors of short-term complications after implantable cardioverter-defibrillator replacement: results from the Ontario ICD Database. Circ Arrhythm Electrophysiol 2011; 4: 136−142. doi: 10.1161/CIRCEP.110.959791
    [22]
    Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010; 122: 1553−1561. doi: 10.1161/CIRCULATIONAHA.110.976076
    [23]
    Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72: 1677−1749. doi: 10.1016/j.jacc.2017.10.053
    [24]
    Dixit S, Kini V. Generator Replacement in Primary Prevention ICD Patients: Is it Time to Develop Guideline Recommendations? JACC Clin Electrophysiol 2017; 3: 1190−1192. doi: 10.1016/j.jacep.2017.04.018
    [25]
    Kawata H, Hirai T, Doukas D, et al. The occurrence of implantable cardioverter defibrillator therapies after generator replacement in patients who no longer meet primary prevention indications. J Cardiovasc Electrophysiol 2016; 27: 724−729. doi: 10.1111/jce.12961
    [26]
    Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008; 52: 1111−1121. doi: 10.1016/j.jacc.2008.05.058
    [27]
    Ellenbogen KA, Levine JH, Berger RD, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006; 113: 776−782. doi: 10.1161/CIRCULATIONAHA.105.561571
    [28]
    Hess PL, Matlock DD, Al-Khatib SM. Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. Clin Cardiol 2020; 43: 187−195. doi: 10.1002/clc.23315
    [29]
    Matlock DD, McGuire WC, Magid M, Allen L. Decision making in advanced heart failure: bench, bedside, practice, and policy. Heart Fail Rev 2017; 22: 559−564. doi: 10.1007/s10741-017-9631-6
    [30]
    Merchant FM, Dickert NW, Jr., Howard DH. Howard DH. Mandatory shared decision making by the centers for medicare & medicaid services for cardiovascular procedures and other tests. JAMA 2018; 320: 641−642. doi: 10.1001/jama.2018.6617
    [31]
    Lewis KB, Carroll SL, Birnie D, et al. Incorporating patients' preference diagnosis in implantable cardioverter defibrillator decision-making: a review of recent literature. Curr Opin Cardiol 2018; 33: 42−49. doi: 10.1097/HCO.0000000000000464
    [32]
    Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 2012; 125: 1928−1952. doi: 10.1161/CIR.0b013e31824f2173
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Article Metrics

    Article views (49) PDF downloads(2) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return